Skip to main content
Pherecydes Pharma logo

Pherecydes Pharma — Investor Relations & Filings

Ticker · ALPHE ISIN · FR0011651694 LEI · 894500LYT3UUN58X3I68 PA Professional, scientific and technical activities
Open in API
Filings indexed 146 across all filing types
Latest filing 2022-03-31 Regulatory Filings
Country FR France
Listing PA ALPHE

About Pherecydes Pharma

https://www.pherecydes-pharma.com/en/

Pherecydes Pharma is a clinical-stage biotechnology company specializing in the research and development of phage therapy to combat antibiotic-resistant bacterial infections. The company develops targeted treatments using bacteriophages, which are naturally occurring viruses that specifically infect and destroy bacteria. Its therapeutic approach focuses on providing personalized solutions for severe infections, particularly those caused by Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli. The company utilizes a proprietary phage bank and a diagnostic tool to determine the most effective phages for each patient's specific bacterial strain. In 2023, Pherecydes Pharma merged with Erytech to form Phaxiam Therapeutics, combining expertise to advance phage therapy as a mainstream anti-infective solution.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is a press release dated March 31, 2022, announcing a research partnership between Pherecydes Pharma and Navarrabiomed regarding phage evaluation for infectious endocarditis. It contains company updates, quotes from management, and contact information. This format is typical of an initial announcement of significant corporate news or a business development, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed financial report (IR). Since it is a formal announcement of a business event (partnership/research agreement) and not a general regulatory filing (RNS) or a specific financial report, it best fits the category for general corporate news or updates that don't fit other specific financial reporting codes. However, given the options, this type of announcement, which is essentially a news release about business operations and strategy, often falls under the general 'Regulatory Filings' (RNS) if a more specific code like 'M&A Activity' (TAR) or 'Capital/Financing Update' (CAP) is not applicable. Since this is a partnership announcement, it is a significant corporate event announcement. It is not a Call Transcript (CT), Earnings Release (ER), or a formal financial report (10-K, IR). It is closest to a general corporate announcement. I will classify it as RNS as the catch-all for significant, non-standard financial disclosures, although it functions like a press release.
2022-03-31 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated March 22, 2022, announcing that Pherecydes Pharma was granted a new patent for its anti-Pseudomonas aeruginosa phages in Europe. It discusses intellectual property, R&D strategy, and provides company background. This type of announcement, focusing on specific corporate developments (like patent grants) released via a press release format, does not fit the definitions for major financial reports (10-K, IR, ER, MRQ) or specific corporate actions (DIV, SHA, POS). It is a general corporate update. Since it is not a standard regulatory filing like a 10-K or a specific report like an AR or SR, and it is not an announcement of a report publication (RPA), the most appropriate general category for a significant, non-financial-results-focused corporate announcement that doesn't fit elsewhere is Regulatory Filings (RNS), which serves as a broad category for miscellaneous official announcements.
2022-03-22 English
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is explicitly titled "PRESS RELEASE" and announces a research collaboration between two entities (Pherecydes Pharma and BIOASTER) regarding a specific medical treatment. It contains forward-looking statements and contact information typical of a corporate announcement, rather than a formal regulatory filing like a 10-K, an earnings report (ER), or a detailed financial report (IR). Since it is a general corporate announcement that doesn't fit the specific categories like M&A (TAR), Director's Dealing (DIRS), or Dividend (DIV), the most appropriate classification is the general regulatory/corporate announcement fallback, RNS (Regulatory Filings), although it functions similarly to an Earnings Release (ER) in format, it lacks financial figures for a period. Given the nature of a press release announcing a strategic partnership, RNS is the best fit among the provided options for a non-standard, material corporate update.
2022-03-11 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and announces a new research collaboration between Pherecydes Pharma and BIOASTER regarding the treatment of bacteremia. It contains forward-looking statements and contact information typical of a corporate announcement, rather than a formal regulatory filing like a 10-K, an official earnings report (ER), or a detailed financial report (IR). Since it is a general corporate announcement about a strategic development (research collaboration) that doesn't fit the specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), it falls best under the general Regulatory Filings/Announcements category, which is RNS, or potentially a general announcement if RNS is reserved for stock exchange specific news. Given the context of financial reporting databases, press releases announcing strategic partnerships often fall into the general regulatory/news category if no other specific code applies. However, since it is a press release announcing a business development, and not a financial result or a mandatory filing, RNS (Regulatory Filings/Miscellaneous) is the most appropriate fallback, although it shares characteristics with an Earnings Release (ER) in format, it lacks the actual financial results. Given the content is purely operational/strategic news, RNS is the best fit among the provided options as a general announcement.
2022-03-11 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is a press release dated March 8, 2022, announcing that Pherecydes Pharma has been granted a patent for its anti-Pseudomonas aeruginosa phages by the Chinese patent office. The content focuses on intellectual property protection, the company's strategy regarding patents, and general company information. This type of announcement, which details specific legal/IP achievements (patent grant) rather than financial results (ER/IR), management changes (MANG), or general regulatory filings (RNS), fits best under the category related to Intellectual Property (IP). It is not a formal regulatory filing like a 10-K or an earnings release, but a specific update relevant to investors concerning proprietary assets.
2022-03-08 French
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is a press release dated March 8, 2022, announcing that Pherecydes Pharma has been granted a patent for its anti-Pseudomonas aeruginosa phages in China. The content focuses on intellectual property protection, the company's strategy regarding phage therapy, and general company information. This type of announcement, which details the status of patents, intellectual property rights, or legal protections, fits best under the 'Intellectual Property' or 'Legal' categories. Since there is no specific code for 'Intellectual Property' and the document is a formal announcement about a legal/IP asset protection, it is most closely related to 'Legal Proceedings Report' (LTR) if it were a lawsuit, but here it is about securing rights. Given the options, and recognizing that patent grants are often treated as significant legal/IP updates, the closest fit among the provided codes that covers legal matters or specific corporate updates outside of standard financial reporting (10-K, ER, IR) is LTR, or potentially RNS as a general regulatory announcement. However, since the core subject is the granting of a patent, which is a form of legal protection, and it is not a standard financial report, LTR (Legal Proceedings Report) is a plausible, though imperfect, fit if we interpret 'Legal' broadly to include IP protection announcements. A stronger argument can be made for RNS (Regulatory Filings) as a general announcement of a material corporate event that doesn't fit elsewhere. Given the focus on IP protection, and lacking a dedicated IP code, RNS is the safest fallback for a material, non-financial press release. Let's re-evaluate: The document is a press release announcing a specific corporate event (patent grant). It is not a financial report (10-K, IR, ER), a management change (MANG), or a shareholder vote result (DVA). It is a specific announcement. RNS is the general regulatory announcement fallback. I will classify it as RNS because it is a press release announcing a material, non-financial corporate development.
2022-03-08 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.